China has been engaged in the R&D and manufacturing of semi-automatic coagulation analyzers for over a decade, and based on the data from the website of the NMPA, in 2024 and 2025 (as od 15 August), a total of 2 instruments from 2 manufacturers have obtained registration certificates...

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news

Keck Medicine of USC physicians are enrolling patients as part of an international clinical trial, designed to assess the safety and efficacy of the antiviral drug DAS181, as a possible treatment for patients with severe COVID-19.

Researchers have discovered that the presence of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in the plasma of women's blood are critical indicators for the prediction of disease recurrence and disease-free survival.

Strains of a common subtype of influenza virus, H3N2, have almost universally acquired a mutation that effectively blocks antibodies from binding to a key viral protein.

After only a few days caring for critically ill COVID-19 patients at the start of the outbreak in New York City, Aakriti Gupta, MD, realized that this was much more than a respiratory disease.

The Rogers group and researchers introduced a novel wearable device and set of data algorithms specifically tailored to catch early signs and symptoms associated with COVID-19 and to monitor patients as the illness progresses.

New research will help health-care practitioners to more accurately diagnose disease and illness in newborn babies from urine samples, according to a study by researchers at the University of Alberta and the Universidad Autónoma de Zacateca

PreTRM is a serum-based proteomic test that uses the ratio of insulin-like growth factor-binding protein 4 (IBP4) to sex hormone-binding globulin (SHBG) to predict the risk of preterm birth.

The American Red Cross has begun testing all blood, platelet and plasma donations for COVID-19 antibodies.

BioFlyte said on Tuesday that it has raised $1.25 million in seed funding, which the company said it will use to accelerate the development of its mass spectrometry-based biothreat detection device. The round was led by venture capital firm

Kidney disease diagnostics firm RenalytixAI announced Friday it has received a clinical laboratory permit from the New York State Department of Health allowing the company to provide its KidneyIntelX test to residents of the state. The test